PMC:1262689 / 13065-14198 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/1262689","sourcedb":"PMC","sourceid":"1262689","source_url":"http://www.ncbi.nlm.nih.gov/pmc/1262689","text":"CGI Clinician Ratings\nFigure 9 depicts the effects of atomoxetine and placebo on ADHD symptom severity change scores for the CGI. As with the CAARS measures, the drug-placebo response curve occupied the space above the diagonal line of no effect and the AUC approximated 0.60, indicating an advantage of atomoxetine over placebo in reducing clinician-rated ADHD severity. Also in accord with the CAARS measures, a small protection from symptom worsening was afforded by atomoxetine, as approximately 10% of subjects who received the drug deteriorated clinically, while approximately twice as many placebo-treated subjects did so. The median change in CGI in the combined group of atomoxetine- and placebo-treated subjects was -1, a response criterion attained by almost 55% of drug-treated subjects but by only approximately 40% of those receiving placebo. As expected, these greater rates of improvement (and protection from deterioration) led to the attainment of lower CGI endpoint scores in the atomoxetine-treated group (Figure 10).\nFigure 9 CGI ADHD Severity (Change Scores).\nFigure 10 CGI ADHD Severity (Endpoint Scores).\n\nD","divisions":[{"label":"Title","span":{"begin":0,"end":21}},{"label":"Figure caption","span":{"begin":1038,"end":1084}},{"label":"Figure caption","span":{"begin":1083,"end":1132}}],"tracks":[{"project":"NEUROSES","denotations":[{"id":"T289","span":{"begin":54,"end":65},"obj":"CHEBI_127342"},{"id":"T290","span":{"begin":304,"end":315},"obj":"CHEBI_127342"},{"id":"T291","span":{"begin":470,"end":481},"obj":"CHEBI_127342"},{"id":"T292","span":{"begin":680,"end":691},"obj":"CHEBI_127342"},{"id":"T293","span":{"begin":999,"end":1010},"obj":"CHEBI_127342"},{"id":"T294","span":{"begin":54,"end":65},"obj":"CHEBI_331697"},{"id":"T295","span":{"begin":304,"end":315},"obj":"CHEBI_331697"},{"id":"T296","span":{"begin":470,"end":481},"obj":"CHEBI_331697"},{"id":"T297","span":{"begin":680,"end":691},"obj":"CHEBI_331697"},{"id":"T298","span":{"begin":999,"end":1010},"obj":"CHEBI_331697"},{"id":"T299","span":{"begin":162,"end":166},"obj":"CHEBI_23888"},{"id":"T300","span":{"begin":533,"end":537},"obj":"CHEBI_23888"},{"id":"T301","span":{"begin":777,"end":781},"obj":"CHEBI_23888"},{"id":"T302","span":{"begin":414,"end":419},"obj":"PATO_0000587"},{"id":"T303","span":{"begin":622,"end":625},"obj":"CHEBI_52027"},{"id":"T304","span":{"begin":671,"end":676},"obj":"CHEBI_24433"},{"id":"T305","span":{"begin":1019,"end":1024},"obj":"CHEBI_24433"},{"id":"T306","span":{"begin":941,"end":944},"obj":"CHEBI_43739"}],"attributes":[{"subj":"T289","pred":"source","obj":"NEUROSES"},{"subj":"T290","pred":"source","obj":"NEUROSES"},{"subj":"T291","pred":"source","obj":"NEUROSES"},{"subj":"T292","pred":"source","obj":"NEUROSES"},{"subj":"T293","pred":"source","obj":"NEUROSES"},{"subj":"T294","pred":"source","obj":"NEUROSES"},{"subj":"T295","pred":"source","obj":"NEUROSES"},{"subj":"T296","pred":"source","obj":"NEUROSES"},{"subj":"T297","pred":"source","obj":"NEUROSES"},{"subj":"T298","pred":"source","obj":"NEUROSES"},{"subj":"T299","pred":"source","obj":"NEUROSES"},{"subj":"T300","pred":"source","obj":"NEUROSES"},{"subj":"T301","pred":"source","obj":"NEUROSES"},{"subj":"T302","pred":"source","obj":"NEUROSES"},{"subj":"T303","pred":"source","obj":"NEUROSES"},{"subj":"T304","pred":"source","obj":"NEUROSES"},{"subj":"T305","pred":"source","obj":"NEUROSES"},{"subj":"T306","pred":"source","obj":"NEUROSES"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"NEUROSES","color":"#bd93ec","default":true}]}]}}